The Institute for Clinical and Economic Review (ICER) confirmed in a recent report that evidence is lacking for outcomes comparisons of ploy-ADP ribose polymerase (PARP) inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.
Though proven to offer superior outcomes versus other treatment regimens, less than half of patients receive standard of care for locally advanced cervical cancer, according to a study published in Gynecologic Oncology.
In a study published in JAMA Oncology, researchers a found that, after adjusting for changes in screening, there was a decrease in all-grade cervical intraepithelial neoplasia (CIN), a known link to cervical cancer, among women 15-19 years old who received the human papillomavirus (HPV) vaccine.
Primary cytoreductive surgery (PCS) may improve survival for patients with stage III ovarian cancer, while neoadjuvant chemotherapy may be the optimal treatment for patients with stage IV disease, reported researchers in the Journal of Clinical Oncology, who examined the use and effectiveness of neoadjuvant chemotherapy in clinical practice.
Administering immunotherapy immediately after chemotherapy may improve response when treating patients with stage IIIC-IV tubo-ovarian high-grade serous carcinoma, according to findings from a study published in Clinical Cancer Research.